Through 2019, Increased Generic Erosion of Key Agents Such as Lamictal and Depakote/Depakote ER Will Cause a Precipitous $2.3 Bi

Dainippon Sumitomo Pharma/Sepracor's Lurasidone Will Become a Market Leader in 2019, According to Findings from Decision Resources

WALTHAM, Mass., Aug. 25  /PRNewswire/ --Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the increased generic erosion of key drugs such as lamotrigine (GlaxoSmithKline's Lamictal, generics) and divalproex (Abbott/Sanofi-Aventis's Depakote/Abbott's Depakote ER, generics), combined with projected generic erosion of the atypical antipsychotic drug class will cause a precipitous $2.3 billion decline in the bipolar disorder drug market over the next decade.

The Pharmacor 2010 findings from the topic entitled Bipolar Disorder reveal that although patient share for atypical antipsychotics will increase through 2019, particularly in France, Germany, Italy, Spain, the United Kingdom and Japan, sales of atypical antipsychotics will decline significantly over the forecast period owing to the generic erosion of key agents such as AstraZeneca/Astellas's Seroquel/AstraZeneca's Seroquel XR, Eli Lilly's Zyprexa, Bristol-Myers Squibb/Otsuka Pharmaceutical's Abilify and Pfizer's Geodon.

The Pharmacor 2010 findings reveal that bipolar depression is the largest unmet need in bipolar disorder, as experts consistently indicate that few therapies achieve sufficient efficacy in this market segment. Two emerging atypical antipsychotics will likely gain approval for bipolar depression: Forest Laboratories/Gedeon Richter/Mitsubishi Pharma's cariprazine and Dainippon Sumitomo Pharma/Sepracor's (soon to be Sunovion Pharmaceuticals) lurasidone. Lurasidone, which is expected to gain approval for bipolar depression in 2012, will become a market leader in 2019.

"The bipolar depression market segment represents the greatest commercial opportunity and we expect that lurasidone will gain approval for bipolar depression in 2012, following its launch in 2011 for the treatment of schizophrenia," said Decision Resources Analyst Alana Simorellis, Ph.D. "Dainippon Sumitomo Pharma and Sepracor will differentiate lurasidone based on its efficacy in bipolar depression, as well as its potential for efficacy in cognitive symptoms, and its relatively mild weight gain profile compared with currently marketed atypical antipsychotics. As a result, we forecast lurasidone to garner peak year sales in the range of $500 million to $1 billion."

About Pharmacor 2010

The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

CONTACT:

Decision Resources, Inc.

Lisa Osgood

+1-781-296-2606

[email protected]

SOURCE Decision Resources

Suggested Articles

Teva is reportedly going for a moonshot with a $15 billion drug offer to settle its opioid cases. It's a plan that might just work, one analyst said.

CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.

Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.